01
Spatial & Temporal Heterogeneity
Genetic mutations differ across regions of the same tumor and evolve rapidly under drug pressure, making a single targeted drug insufficient.
Solid Tumor Treatment · Precision · Innovation · Integration
GHG is not a single technology — it is a complete solid-tumor treatment system. Supported by clinical research and multidisciplinary comprehensive care, we deliver a full-cycle solution from precision assessment and individualized decision-making to local control and systemic immune reconstitution.
Five Core Dilemmas in Solid Tumor Treatment
These "unmet needs" drive our continuous innovation — moving from single-agent therapy to integrated, multi-modality comprehensive care.
02
Immunosuppressive Microenvironment
Dense stroma and aberrant vessels form physical barriers and drive T-cell exhaustion — the tumor 'wall' that resists immunotherapy.
03
Lack of Perfect Targets
Most solid-tumor antigens are tumor-associated (TAAs) also expressed in normal tissue — creating on-target off-tumor toxicity.
04
Distant Metastasis & Barriers
Early micrometastasis and physiological barriers (e.g. blood-brain barrier) reduce the efficacy of systemic therapies.
05
Uneven Access to Advanced Therapy
Global variation in medical standards and access to innovative drugs limits patient options.
Paradigm Shift
From lesion clearance / growth suppression to precise identification + immune remodeling + comprehensive integration.
1.0
Lesion Clearance
Surgery, radiotherapy — local attack
2.0
Growth Suppression
Chemotherapy — systemic attack
3.0
Mutation Identification
Targeted therapy — precision attack
4.0
Immunity Reconstruction
Cell therapy & immunotherapy — remodeling the immune environment
Five Key Technology Platforms
Coordinated tools within GHG's individualized comprehensive treatment system for common and refractory solid tumors.
01
Key Technology 01
Organoid-on-a-Chip · Personalized Drug Sensitivity Platform
Patient-substitute drug testing and immune-response assessment in vitro
- Substitute drug testing — recapitulates tumor characteristics and screens regimens, reducing the risk of blind trials.
- Drug sensitivity & resistance — guides medication when multiple drugs are available or later-line options are exhausted.
- Immune-response assessment — reconstitutes the tumor immune microenvironment with PBMCs to evaluate PD-1/PD-L1, CAR-T and TIL responses.
Ideal for
Drug resistance, unclear targets, rare/difficult tumors, immunotherapy evaluation.
02
Key Technology 02
Immuno-targeting & Innovative Drug Platform
From activating existing immunity to rebuilding immune capacity
- Efficient new-drug introduction — access to innovative drugs for R/R solid tumors, often years ahead of overseas availability.
- TIL therapy — personalized, broad-spectrum use of the patient's tumor-reactive lymphocytes; covers complex heterogeneous antigens.
- CAR-T / CAR-NK for solid tumors — precision targeting of CLDN18.2, HER2, GD2 and GPC3.
Ideal for
Refractory / relapsed solid tumors, cases requiring next-generation immunotherapy.
03
Key Technology 03
Local Interventional Therapy · Minimally Invasive, Precise, Repeatable
Vascular and non-vascular interventions for local control and combination synergy
- Vascular intervention — HAIC, TACE, TAE, portal vein stent implantation.
- Non-vascular intervention — image-guided percutaneous ablation (HIFU, RFA, cryoablation, microwave), chemical ablation and drainage (PTCD, nephrostomy).
- Broad disease coverage — liver, lung, breast, bone and soft-tissue sarcoma; combines with radiotherapy, immunotherapy and cell therapy.
Ideal for
Local control, symptom relief, bridging or combination synergy in complex cases.
04
Key Technology 04
Proton Therapy · High-Precision Radiotherapy & Tissue Protection
IBA Proteus® PLUS system with international MDT oversight
- International MDT oversight — precise indication matching and individualized planning.
- Extensive experience — pediatric tumors, tumors adjacent to critical organs, re-irradiation and complex deep-seated solid tumors.
- World-leading equipment — stable beam, precise dose shaping and motion management.
- Full-process QA — standardized quality control, on-site engineering support, comprehensive pre/intra/post-treatment management.
Ideal for
Complex, deep-seated tumors or lesions adjacent to radiosensitive organs.
05
Key Technology 05
Radionuclide Therapy · Targeted Radioligand Therapy
Precise closed loop of diagnostic localization → targeted delivery → efficacy assessment
- Precise tumor targeting — PSMA-targeted delivery of Lu-177 for advanced prostate cancer; β-radiation damages DNA and kills cancer cells while sparing healthy tissue.
- Better tolerability — less systemic toxicity than conventional chemotherapy.
- Minimally invasive — administered by IV infusion; no surgery required.
- MDT-driven — nuclear medicine, urology, medical oncology and medical physics collaborate; shielded inpatient rooms meeting international safety standards.
Ideal for
Advanced prostate cancer (Lu-177 PSMA); expanding portfolio of radioligand therapies.
Capability Matrix for Common & Refractory Solid Tumors
With MDC/MDT as the decision-making core, precision diagnosis as navigation, and multi-technology platforms as the tools — supported by oncologic critical care and supportive care as the safety boundary.
Digestive Tumors
Stomach · Esophagus · Colorectal · Liver · Gallbladder · Pancreas
Thoracic Tumors
Lung Cancer · Mediastinal Tumors · Thoracic Metastases
Breast & Gynecological
Breast Cancer · Ovarian Cancer · Cervical Cancer
Bone & Soft-Tissue Sarcomas
Osteosarcoma · Soft-Tissue Sarcoma
Melanoma & Urinary System
Melanoma · Prostate · Kidney · Bladder Cancer
Other Refractory Tumors
Nervous-System Tumors · Rare Tumors
Free Case Feasibility Assessment
Start your medical journey to China
Based in Hong Kong and serving international patients, Privilege Medical bridges you to leading Class 3A and JCI-accredited hospitals in mainland China. We do not provide medical care directly — we coordinate specialist matching, medical visa support and on-the-ground concierge from your first enquiry to post-treatment follow-up.
Complete the form below. Our coordination team responds within 1–2 business days with a complimentary assessment covering clinical feasibility, specialist matching and an indicative admission timeline.
Privacy Notice
Privilege Medical is a Hong Kong–based medical concierge and does not provide clinical care. Personal data and medical information you submit are collected, held and used strictly for the purposes of case assessment, specialist matching and coordination of medical services in mainland China, in accordance with the Personal Data (Privacy) Ordinance (Cap. 486) of Hong Kong.
Your data may be transferred to our partner hospitals, treating clinicians and authorised service providers (including translators and travel coordinators), some of whom are located outside Hong Kong. We take reasonable steps to keep your information confidential and secure, and we do not sell your data to any third party.
You have the right, under the PDPO, to request access to and correction of the personal data we hold about you, and to withdraw consent at any time by writing to service@privilegemedical.com. Information submitted via this form is not encrypted end-to-end; please avoid including highly sensitive identifiers (e.g. ID numbers) in the free-text fields.